We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629.
- Authors
Bratland, Åse; Munoz-Couselo, Eva; Mortier, Laurent; Roshdy, Osama; González, Rene; Schachter, Jacob; Arance, Ana M.; Grange, Florent; Meyer, Nicolas; Joshi, Abhishek Jagdish; Billan, Salem; Hughes, Brett G. M.; Grob, Jean-Jacques; Ramakrishnan, Karthik; Ge, Joy; Gumuscu, Burak; Swaby, Ramona F.; Gutzmer, Ralf
- Abstract
Introduction: At first interim analysis of KEYNOTE-629, health-related quality of life (HRQoL) with pembrolizumab was stable or improved over 48 weeks in recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC). HRQoL results from the second interim analysis in R/M or locally advanced (LA) cSCC are presented. Methods: Patients received pembrolizumab 200 mg every 3 weeks for ≤ 2 years. Change in EORTC Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EQ-5D-5L scores were exploratory end points. Primary analysis was performed at week 12 to ensure adequate completion/compliance. Descriptive analyses were also conducted through weeks 48 and 75 for the LA and R/M cohorts, respectively. Results: At data cutoff (29 July 2020), mean scores in the LA cohort (n = 47) were stable from baseline to week 12 for EORTC QLQ-C30 global health status (GHS)/quality of life (QoL) (−0.27 points [95% confidence interval (CI) −10.93 to 10.39]), physical functioning (−1.29 points [95% CI −8.77 to 6.19]), and EQ-5D-5L visual analog scale (2.06 [95% CI −7.70 to 11.82]). HRQoL remained stable through week 48 in the LA cohort; 76.6% and 74.5% of patients had improved or stable GHS/QoL and physical functioning scores, respectively. HRQoL continued to show stability or improvement through week 75 in the R/M cohort (n = 99); 71.7% and 64.6% of patients had improved or stable GHS/QoL and physical functioning scores, respectively. Conclusions: Pembrolizumab has demonstrated antitumor activity and manageable safety. The current analysis shows pembrolizumab treatment preserved HRQoL. Collectively, these results support pembrolizumab as standard of care for LA or R/M cSCC. Trial Registration: ClinicalTrials.gov, NCT03284424—September 15, 2017.
- Subjects
SQUAMOUS cell carcinoma; QUALITY of life; PHYSICAL mobility; PEMBROLIZUMAB; VISUAL analog scale
- Publication
Dermatology & Therapy, 2023, Vol 13, Issue 12, p3165
- ISSN
2193-8210
- Publication type
Article
- DOI
10.1007/s13555-023-01059-y